Anastrozole
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Reduces circulating estradiol (E2) by reversibly inhibiting the aromatase enzyme that converts androgens (testosterone, androstenedione) to estrogens.
The primary danger of anastrozole is using too much — crashed estrogen destroys joints, libido, and cognition faster than elevated estrogen ever would.
Reduces circulating estradiol (E2) by reversibly inhibiting the aromatase enzyme that converts androgens (testosterone, androstenedione) to estrogens. Used to prevent and manage gynecomastia on anabolic steroid cycles, control estrogenic side effects at supraphysiological testosterone doses, and manage estradiol on TRT in men with confirmed symptomatic high E2.
Crashed estrogen is the primary danger — over-suppression causes bilateral joint pain, complete libido loss, cognitive fog, and depression. Long-term use causes bone mineral density loss (ATAC trial: 11% fracture rate at 10 years vs 7.7% tamoxifen). HDL cholesterol drops dose-dependently. Individual response varies 3-10x between users.
Highly effective, well-understood, inexpensive estrogen management with decades of clinical and community data — but only when blood-tested and monitored. Most TRT users do not need it at all.
High for confirmed elevated E2 when dosed conservatively and guided by bloodwork. Effectiveness deteriorates rapidly when over-dosed — too much AI is more damaging than too little.
Never combine anastrozole with letrozole or exemestane — stacked aromatase inhibitors create additive E2 suppression with no benefit and extreme crash risk.
Intro
Anastrozole was developed by AstraZeneca in the early 1990s and FDA-approved in 1995 under the brand name Arimidex for treatment of estrogen receptor-positive breast cancer in postmenopausal women.
In the landmark ATAC trial (5,000+ patients, 10-year follow-up), anastrozole demonstrated superior disease-free survival versus tamoxifen for early-stage ER+ breast cancer. The bodybuilding and TRT communities adopted it in the late 1990s as a means of controlling estradiol on anabolic steroid cycles — a fundamentally different context than its clinical indication with different dosing requirements.
Anastrozole belongs to the third generation of aromatase inhibitors. First-generation AIs like aminoglutethimide suppressed cortisol alongside estrogen and are obsolete. Third-generation drugs including anastrozole, letrozole, and exemestane are highly selective for CYP19A1 aromatase with minimal off-target effects on other steroidogenic pathways. At 1mg daily, anastrozole suppresses whole-body aromatization by approximately 97% and plasma estradiol by approximately 70% in postmenopausal women. In men on TRT, lower doses targeting 40-80% E2 reduction are typical.
The mechanistic distinction that matters most to users: anastrozole is reversible. It competitively occupies aromatase's active site without forming a covalent bond. When anastrozole clears (half-life approximately 40-50 hours), enzyme activity returns. An estrogen crash from anastrozole self-corrects within 7-14 days of stopping — unlike exemestane (Aromasin), which permanently deactivates aromatase so a crash lasts until new enzyme is synthesized.
For men, anastrozole has legitimate off-label clinical applications: familial aromatase overexpression, idiopathic gynecomastia, and hypogonadism with hyperestrogenism. But the dominant community use case is managing estradiol during exogenous testosterone administration. The current (2025-2026) expert consensus has shifted considerably — most TRT-aware clinicians and experienced community educators now hold that most men on standard TRT doses never need an AI at all, and that routine prophylactic AI prescribing represents over-treatment.
Observed Effects
Estradiol suppression (dose-dependent): Anastrozole reduces plasma E2 in a dose-dependent fashion.
At 1mg/day (clinical dose), estradiol is suppressed approximately 70% and whole-body aromatization by approximately 97%. In TRT community use (0.25-1mg/week total), users report E2 reductions of 40-70% from baseline, bringing E2 from symptomatic-high ranges (above 60 pg/mL) into community target range (20-35 pg/mL). Individual response varies 3-10x based on aromatase expression levels, body fat percentage, and testosterone dose.
Gynecomastia prevention: Anastrozole prevents gynecomastia by reducing E2 before it acts on breast ER-alpha receptors. Effective for prevention of new tissue formation. Not effective for reversing established glandular tissue — SERMs (tamoxifen, raloxifene) are required for that. The AI prevents; the SERM reverses.
Estrogenic symptom control: At correctly calibrated doses confirmed by bloodwork, anastrozole reduces water retention (E2-mediated sodium retention), may improve muscle definition, and can stabilize mood in users with genuinely elevated E2. However, many symptoms attributed to high estrogen occur within normal E2 range — misattribution is common.
Total testosterone modulation (HPG-intact men): In men with residual HPG axis function, anastrozole's reduction of E2 removes negative feedback on the hypothalamic-pituitary axis, increasing LH/FSH and therefore endogenous testosterone. In fully suppressed AAS users this effect is absent. In TRT users on HCG, AI can modestly elevate total T by allowing HPG activity alongside the HCG stimulus.
Field Reports
The dominant community narrative around anastrozole is the crash story. Reports of crashing E2 and taking weeks to feel human again appear across hundreds of TRT-forum threads.
The specific symptom cluster — bilateral joint pain that moves around (hands one week, knees the next), complete libido shutdown, mental fog severe enough to impair reading, and a depression that does not respond to normal interventions — is almost universally recognized in experienced AAS communities.
The dosing controversy: TRT-forum threads consistently flag that many doctors prescribe 1mg daily because it is the only commercially available tablet. The community consensus is that 0.25-0.5mg/week is appropriate for standard TRT. The am-I-being-over-prescribed thread format is a staple of TRT forums.
Bloodwork versus symptoms: A persistent debate about whether anastrozole can be dosed by feel. The consensus answer is no — high E2 symptoms and low E2 symptoms overlap too much (both cause fatigue, mood changes, and libido issues). Multiple users document dosing in the wrong direction based on symptom interpretation alone, worsening the problem they were trying to fix.
The less-is-more philosophy: A subset of experienced users argue they feel best at E2 of 40-60 pg/mL, well above what many clinics target. Experienced practitioner-educators explicitly defend contextual AI use and rebut both extremes. The let-it-run approach has gained traction as the community matures.
Long-term use regret: A documented community thread on enduring side effects five years after prolonged high-dose anastrozole use reports persistent joint damage and reduced bone density. A long cancer-support forum thread with DEXA-confirmed bone-loss reports serves as the anchor reference for community warnings about chronic use without monitoring.
Community Consensus
Anastrozole has been in community use since the late 1990s, making it among the most discussed compounds in the AAS/TRT ecosystem.
The trajectory of community thinking has shifted through distinct phases. Early adoption saw AI prescribed almost universally with testosterone — the assumption was that high estrogen was always bad. The 2010s brought the crashed estrogen revelation as a generation of forum posts documented devastating over-suppression experiences.
The current (2025-2026) community consensus, as expressed on large TRT forums and recent practitioner-educator content, is a confirm-before-treating paradigm: get a sensitive E2 test before initiating, confirm symptoms correlate with labs, start at the lowest effective dose, and adjust with bloodwork. The growing less-is-more camp argues that estradiol at the high-physiological range (40-60 pg/mL) provides benefits for muscle protein synthesis, bone health, and libido that outweigh the cosmetic cost of water retention.
The over-prescribing criticism of traditional TRT clinics persists across forum threads. Multiple users document being prescribed 1mg daily tablets — the only commercially available dose — when optimal TRT dosing is often 0.1-0.25mg twice weekly. This mismatch between pharmaceutical packaging and optimal male TRT dosing is a recurrent community frustration and a driver of the research-chemical liquid market.
Practitioner-educator consensus has converged on contextual use with bloodwork monitoring, explicitly rebutting both the AIs-are-the-devil camp and the always-use-an-AI camp as dogmatic extremes. The tools are not the problem; indiscriminate use without testing is.
Risks & Monitoring
Crashed estrogen — most common and most serious adverse effect: Bilateral joint pain, zero libido, cognitive fog, and depression constitute the crashed E2 syndrome.
Joint pain is typically migratory arthralgia moving between knees, hips, hands, and wrists week to week. Libido loss is often complete. Cognitive effects include word-finding failure, poor working memory, and reading comprehension impairment. The depression from crashed E2 is distinctly flat and unresponsive to normal interventions. Onset typically 2-6 weeks after starting or dose increase. Recovery after stopping: E2 rebounds within 7-14 days given anastrozole's 40-50h half-life.
HDL cholesterol reduction (very common with sustained use): Estradiol upregulates hepatic HDL production via ER-alpha in liver cells. Suppressing E2 reduces HDL dose-dependently. Clinical meta-analysis data and community bloodwork reports both confirm HDL reduction as a consistent anastrozole effect. Men with baseline HDL below 40 mg/dL face meaningful additional cardiovascular risk.
Bone mineral density loss (long-term, common with extended use): ATAC trial 10-year data: 11% fracture rate with anastrozole vs 7.7% with tamoxifen. BMD loss at lumbar spine and femoral neck is progressive with duration. Community first-person reports include DEXA-scan-confirmed bone loss in men after years of continuous high-dose use. Annual DEXA recommended for men using anastrozole continuously beyond 12 months.
Impaired erection quality (common): Estradiol plays a direct role in penile nitric oxide signaling and corpus cavernosum smooth muscle function. E2 crash commonly causes erectile dysfunction that does not respond to PDE5 inhibitors — the issue is neurochemical, not vascular.
Musculoskeletal symptoms (common): Arthralgia, morning stiffness, reduced joint range of motion. ATAC trial: 35.6% musculoskeletal event rate vs 29.4% for tamoxifen.
Rare adverse effects: Liver enzyme elevation at high doses, thrombotic events, paradoxical partial ER activation at very low E2 concentrations (anastrozole may weakly activate ER when competing with near-absent estradiol — understudied but reported in TRT forum literature).
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Standard immunoassay E2 tests are inaccurate for men and cross-react with compounds like trenbolone. LC-MS/MS sensitive assay is required for accurate readings. Baseline confirms E2 is actually elevated before starting AI. Target range for men on TRT: 20-35 pg/mL.
Retest 4-6 weeks after initiating or changing anastrozole dose. Symptoms alone cannot distinguish high E2 from low E2 — both cause fatigue, mood changes, and libido issues. Bloodwork is the only reliable differentiation.
Anastrozole reduces HDL dose-dependently. Baseline establishes the reference point and flags users who should be cautious before chronic use. Men with HDL below 40 mg/dL at baseline should weigh AI use carefully given additional suppression.
Monitor HDL every 3-6 months on continuous anastrozole use. HDL decline greater than 20% from baseline warrants dose reassessment.
Required context for interpreting E2. A T of 800 ng/dL with E2 of 45 pg/mL is very different from T of 1500 ng/dL with E2 of 45 pg/mL. The T:E2 ratio informs whether to adjust testosterone dose versus AI dose.
Annual DEXA for men using anastrozole continuously beyond 12 months. Estradiol is essential for bone mineral density maintenance in men. ATAC trial confirmed progressive bone loss; community reports include DEXA-confirmed osteoporosis progression.
Avoid With
Do not combine Anastrozole with the following. Sorted highest-severity first.
Why:Both are non-steroidal competitive aromatase inhibitors. Concurrent use provides no additional benefit over either alone at maximum dose but dramatically increases crash risk through additive suppression. Letrozole alone suppresses E2 by 95-98% — combined with anastrozole, essentially no E2 remains.
What to do:Never combine two aromatase inhibitors. If switching from anastrozole to letrozole or vice versa, stop one completely before starting the other.
Why:Steroidal suicidal AI plus competitive reversible AI creates additive and potentially irreversible E2 crash. Combined effect is unpredictable with extreme crash risk and prolonged recovery.
What to do:Aromasin and anastrozole are alternatives, not complements. Choose one.
Why:5-AR inhibitors block testosterone conversion to DHT. DHT competes with testosterone for aromatase substrate sites, naturally reducing aromatization. Removing DHT via 5-AR inhibitors means more testosterone is available for E2 conversion — E2 tends to rise. Users on finasteride or dutasteride may need more anastrozole to achieve the same E2 target.
What to do:Not a contraindication but requires dose adjustment awareness. Retest E2 sensitive when adding or removing 5-AR inhibitors.
Why:Using anastrozole prophylactically on standard TRT doses (100-200mg/week) without confirmed E2 elevation is a common mistake. Most TRT patients do not generate sufficient E2 to require AI. Prophylactic use creates crash risk with zero benefit.
What to do:Confirm E2 elevation with sensitive assay before initiating. Current expert consensus: most men on TRT do not need an AI.
Why:Trenbolone metabolites cross-react with standard immunoassay E2 tests, producing falsely elevated E2 readings. Users may dose anastrozole based on a spurious high E2, actually crashing true E2. Always use LC-MS/MS sensitive assay when trenbolone is in the stack.
What to do:Not a direct drug interaction — an assay interference that can cause dangerous dosing errors.
Protocols By Goal
On-Cycle Gyno Prevention (Blast): Start anastrozole 0.5mg EOD from week 1. Confirm E2 at target range (20-35 pg/mL) via sensitive assay at week 4-6.
At first sign of gyno tissue tenderness (nipple sensitivity, small lump beneath areola), add tamoxifen 20mg/day — AI alone is insufficient for developing glandular tissue.
TRT Estrogen Management: Do not initiate AI prophylactically. Confirm elevated E2 (above 50 pg/mL on sensitive assay, or symptomatic) before starting. First optimize injection frequency — switching to twice-weekly or daily subQ often resolves E2 issues without medication. If AI is needed, begin 0.25mg twice weekly, retest in 6 weeks, adjust in small increments. If asymptomatic at E2 40-50 pg/mL, consider holding AI — many men benefit from E2 in this range (bone health, libido, muscle protein synthesis).
Blast-and-Cruise: Maintain 0.5mg EOD during blast. As T dose reduces to cruise (100-200mg/week), taper anastrozole proportionally — most men can return to 0.25mg twice weekly or eliminate AI entirely on cruise. Retest E2 sensitive 4-6 weeks after dose reduction.
Crash Recovery: Stop anastrozole immediately. Do not add SERMs or other compounds during recovery — let E2 rebound naturally. Anastrozole's 40-50h half-life means it clears in approximately 5-7 days; E2 then rebounds over the following week. Full symptom resolution typically 7-14 days. Reintroduce at 50% of the prior dose with bloodwork confirmation before resuming.
Dosing Details
TRT Conservative Start (most men on 100-200mg/week testosterone): Common conservative community starts are 0.125-0.25mg twice weekly (0.25-0.5mg/week total), often timed with testosterone injections or 24 hours post-injection to align AI peak with T/aromatization peak. Standard TRT users are commonly warned away from starting at 0.5mg EOD. Sensitive E2 is usually retested at 4-6 weeks and adjusted in 0.125mg increments. Most men will either not need AI at all or will stabilize at 0.25mg twice weekly.
TRT Maintenance (confirmed responder): 0.25mg twice weekly (0.5mg/week total) is the most commonly cited stable maintenance dose for men on standard TRT who genuinely need an AI. Some achieve control at 0.125mg twice weekly. Bloodwork every 6-12 months is the observed monitoring pattern.
Tanner Formula (rough estimate): Weekly testosterone dose in mg divided by 500 equals weekly anastrozole dose in mg. Example: 500mg/week testosterone equals 1mg/week anastrozole. 250mg/week equals 0.5mg/week. This is an average approximation - individual titration via bloodwork is still required.
Blast Cycle Moderate (400-600mg/week aromatizing steroids): 0.5mg EOD (1.75mg/week total) appears in community protocols. Many users on 500mg/week still do not need this full dose, so the safer observed pattern is lower starting exposure with lab-guided titration.
Blast Cycle Aggressive (700mg+/week, stacked aromatizing compounds): 0.5-1mg EOD (up to 3.5mg/week) appears in high-testosterone or aromatizing-stack contexts, including nandrolone or boldenone. 1mg EOD approaches clinical breast-cancer dosing and carries high crash risk. Mandatory bloodwork at 4-6 weeks is the safety spine in these reports.
Gyno Emergency: Some reports use 0.5mg daily for 7-14 days to rapidly reduce E2, then taper to maintenance, with tamoxifen 20mg/day added if existing gyno tissue is present. This is high-risk endocrine management and should not be treated as reader-specific instruction.
Daily SubQ testosterone users: Daily subcutaneous testosterone injections stabilize T serum levels, eliminating weekly peaks that drive most aromatization spikes. Many daily subQ users find they can significantly reduce or eliminate anastrozole versus their previous weekly injection protocol.
Stacks & Alternatives
The foundational use case. Anastrozole exists to manage estradiol generated by testosterone aromatization. Testosterone dose determines how much aromatization occurs and therefore how much AI (if any) is required.
HCG stimulates Leydig cell testosterone production, increasing endogenous T and therefore increasing aromatization. Men on TRT plus HCG typically need modestly more anastrozole than TRT alone.
Both aromatize and add to total estrogenic load alongside testosterone. Combined aromatization of a Deca plus testosterone stack typically requires more anastrozole than testosterone alone.
Distinct mechanism — tamoxifen blocks ER in breast tissue, treating existing gyno. AI reduces E2 production, preventing new tissue. For active gyno flare, combine AI plus SERM: AI lowers E2 substrate, tamoxifen blocks remaining E2 action at breast ER.
Alternatives
Stack Cost
Moderate tax: anastrozole is inexpensive and reversible, but it spends endocrine-monitoring capacity because too much AI can crash E2, worsen HDL, and erode bone density during chronic use.
The article says symptoms cannot reliably distinguish high E2 from low E2, response varies 3-10x, and sensitive E2 bloodwork is required before starting and after dose changes.
The adverse-effects section describes dose-dependent HDL reduction and long-term BMD loss, with annual DEXA recommended for continuous use beyond 12 months.
stackingConflicts marks other aromatase inhibitors as hard conflicts and flags 5-AR inhibitors and trenbolone assay interference as contexts that can cause dosing mistakes.
The article describes anastrozole as inexpensive and widely available, with the main access problem being tablet size rather than raw cost.
- ·Counts as the aromatase-inhibitor lane; do not combine with letrozole, exemestane, or another AI.
- ·Counts as an endocrine-monitoring lane; use sensitive estradiol testing instead of symptom-only dosing.
- ·Do not add it prophylactically to standard TRT when E2 is not confirmed high.
- ·Retest E2 after adding or removing HCG, finasteride, dutasteride, or a major aromatizing steroid dose change.
- ·For chronic use, reserve capacity for lipid tracking and bone-density follow-up.
- ·Sensitive estradiol assay at baseline and 4-6 weeks after initiation or dose change.
- ·Total testosterone context for interpreting the T:E2 ratio.
- ·Baseline and follow-up lipid panel when use continues beyond a short correction.
- ·Annual DEXA planning for continuous use beyond 12 months.
- ·Accurate fractional dosing setup if using liquid anastrozole.
The ordinary TRT use case is reversible when stopped, but misuse can rapidly create joint, libido, mood, HDL, and long-term bone problems. The article repeatedly requires bloodwork-guided titration.
- ·Using anastrozole prophylactically on standard TRT
- ·No access to sensitive E2 testing
- ·Baseline HDL is already low or bone-density risk is present
- ·Plan includes another aromatase inhibitor
The article states anastrozole is reversible with a 40-50 hour half-life and that crashed E2 usually rebounds within 7-14 days after stopping.
- ·Temporary joint pain, low libido, mood flattening, or brain fog while E2 rebounds
- ·Need to avoid adding more compounds during crash recovery
- ·Reintroduction should start at about half the prior dose only after lab confirmation
Use LC-MS/MS sensitive estradiol testing, wait for steady state, and adjust in 0.125 mg increments.
Use fractional dosing or a reliable liquid preparation, and begin with the conservative TRT range described in the article.
Choose one AI if an AI is needed at all. Stop one before switching and use labs to guide the new dose.
Track lipids during sustained use, keep the lowest effective dose, and add annual DEXA if use becomes chronic.
The article says standard assays and symptoms can mislead dosing, especially in male TRT/AAS ranges.
stackingConflicts marks concurrent AI use as a hard conflict because additive suppression creates extreme crash risk.
The article identifies HDL suppression and long-term BMD loss as the major chronic-use liabilities.
womenConsiderations marks pregnancy contraindication and menstrual disruption as central female-use constraints.
Practical Setup
Liquid versus tablet: Commercially produced anastrozole tablets come in 1mg — the breast cancer therapeutic dose.
For TRT users who need 0.125-0.5mg per dose, low-dose liquid or compounded formats are commonly used. The practical issue is dose consistency: suspensions can settle, causing severe dose inconsistency if not prepared and measured correctly.
Sensitive versus standard E2 assay: The sensitive (LC-MS/MS) estradiol assay is required, not optional. Standard immunoassays are designed for postmenopausal women with very low E2 and are inaccurate in the 10-50 pg/mL range where men operate. If on trenbolone, sensitive assay is mandatory — trenbolone metabolites cross-react with standard assays, producing falsely elevated E2 readings that can drive catastrophic AI over-dosing.
Half-life implications for dosing: Anastrozole's 40-50 hour half-life means: steady-state takes 7-10 days after starting or changing dose; the full effect of a dose change is not felt for 1-2 weeks so do not stack dose increases; E2 rebounds naturally within 7-14 days of stopping. Daily subcutaneous testosterone injections stabilize T serum levels versus weekly peaks, reducing aromatization spikes and often allowing lower anastrozole doses or complete elimination.
Biomarkers to monitor: Estradiol sensitive (target 20-35 pg/mL for most TRT users), Total testosterone (for T:E2 ratio context), HDL cholesterol (track decline from baseline), LDL cholesterol, SHBG (for free E2 interpretation). Long-term users: annual DEXA bone density scan. Optional: CBC (hematocrit), CMP (liver enzymes for anastrozole's hepatic CYP450 metabolism).
Mechanism Deep Dive
Reversible competitive aromatase inhibition (CYP19A1): Anastrozole competitively binds the active site of CYP19A1 — the cytochrome P450 enzyme responsible for the final step in estrogen biosynthesis: conversion of androgens (testosterone, androstenedione) to estrogens (estradiol, estrone). The competition is reversible — anastrozole occupies the active site without forming a covalent bond, and enzyme activity returns as anastrozole concentrations fall below effective inhibitory threshold. This reversibility distinguishes it from exemestane, which alkylates the active site (suicidal inhibition). At therapeutic concentrations, anastrozole reduces whole-body aromatization by approximately 97% in clinical populations.
Selectivity versus other aromatase inhibitors: Anastrozole and letrozole are both triazole-based non-steroidal AIs, but letrozole has approximately 4-5x greater binding affinity for aromatase. Clinical effect: letrozole suppresses E2 by 95-98% at 2.5mg/day versus anastrozole's 70% at 1mg/day. Both drugs spare other CYP450-mediated steroidogenic pathways — no suppression of cortisol, aldosterone, or thyroid hormones at therapeutic doses. This selectivity advantage over first-generation aminoglutethimide (which suppressed cortisol) makes third-generation AIs the standard.
Half-life and dosing frequency implications: Anastrozole's plasma half-life of 40-50 hours supports once-daily dosing in clinical protocols. Community TRT and blast-cycle use typically employs twice-weekly or EOD dosing at lower total doses — targeting partial suppression rather than near-complete. Practical consequences: steady-state requires approximately 8 days; a missed dose creates a coverage gap; E2 rebounds within 7-14 days of stopping. Compare to exemestane's suicidal binding, which provides consistent suppression regardless of serum level fluctuations — this explains why some users prefer exemestane's stability despite its irreversibility.
DHT as natural aromatase competitor: Dihydrotestosterone (DHT) is not a substrate for aromatase and competes with testosterone for aromatase binding sites, naturally reducing the fraction of testosterone converted to estradiol. 5-alpha-reductase inhibitors (finasteride, dutasteride) that block testosterone-to-DHT conversion eliminate this natural buffer, increasing the testosterone fraction available for aromatization and raising E2. This mechanism explains why finasteride and dutasteride users often need more AI to achieve the same E2 target, and why DHT-derivative compounds like masteron and primobolan can reduce E2 even without being traditional aromatase inhibitors.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
In the landmark ATAC trial (5,000+ patients, 10-year follow-up), anastrozole demonstrated superior disease-free survival versus tamoxifen for early-stage ER+ breast cancer.
The article uses this to establish clinical depth and long-term safety signals. It should not be read as direct evidence for male E2-management protocols.
At 1mg daily, anastrozole suppresses whole-body aromatization by approximately 97% and plasma estradiol by approximately 70% in postmenopausal women.
Male TRT dosing is usually lower and targets partial suppression; the article explicitly separates this from 1 mg/day oncology dosing.
In TRT community use (0.25-1mg/week total), users report E2 reductions of 40-70% from baseline.
This is practical community bloodwork synthesis in the article, not a controlled clinical effect size.
ATAC trial 10-year data: 11% fracture rate with anastrozole vs 7.7% with tamoxifen. BMD loss at lumbar spine and femoral neck is progressive with duration.
The article transfers this as a chronic low-estrogen risk signal. The magnitude may not match short-term male TRT microdosing, but it supports DEXA concern during continuous use.
ATAC trial: 35.6% musculoskeletal event rate vs 29.4% for tamoxifen.
This anchors the musculoskeletal adverse-effect signal; community crash reports describe a different lower-dose male context.
Begin at 0.125-0.25mg twice weekly (0.25-0.5mg/week total) for most men on 100-200mg/week testosterone who genuinely need an AI.
The article treats this as a conservative starting protocol that still requires sensitive E2 retesting at 4-6 weeks.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.